molecular hydrogen + minocycline

H2M is a novel combination therapy consisting of molecular hydrogen (H2) and the tetracycline antibiotic minocycline, currently under investigation by Stony Brook University for the treatment of acute ischemic stroke. Molecular hydrogen acts as a potent antioxidant and scavenger of reactive oxygen species (ROS), helping to mitigate oxidative stress and ischemia/reperfusion injury. Minocycline provides complementary neuroprotection by inhibiting the activation of matrix metalloproteinase-9 (MMP-9) and poly(ADP-ribose) polymerase (PARP), pathways that contribute to blood-brain barrier disruption and neuronal death following a stroke. The therapy is administered as hydrogen-enriched water or saline alongside minocycline (delivered intravenously or orally) within 24 hours of stroke onset. This dual-action approach is being evaluated in a pilot randomized controlled trial to improve neurological recovery and protect brain tissue in the acute phase of ischemic stroke.

Other names

H2M therapyH-2M therapyH 2M therapyHydrogen and Minocycline combination therapy